Definitive Contract 140D0426C0013
Award Date 2/26/26
Potential Completion Date 3/31/27
Potential Value $600K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed Set-Aside Type
Total Small Business
Federal Contract Vehicle
- Not listed
Extent Competed
Not listed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
College Station, TX, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Other Statutory Authority
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institutes of Health awarded a $600,000 firm fixed-price contract to Quantitative Biosciences, Inc., a San Diego-based small business, for cell and gene therapy process analytical technology and quality control testing. The contract was awarded on February 26, 2026, with an ultimate completion date of March 31, 2027, under a total small business set-aside designation. This effort supports the NIH's mission to advance biomedical research by developing critical analytical and...
- Halcyon Biomedical Inc., a small business, was awarded a $600,000 firm fixed-price contract by the National Institutes of Health on March 2, 2026, for development of a point-of-care system for cell therapy manufacturing and delivery. The contract, set aside exclusively for small businesses, is scheduled for completion by September 1, 2027, and will be performed in Friendswood, Texas. This award originated from an Advanced Research Projects Agency for Health (ARPA-H) Small Business Innovation...
- This is a $1,749,858.00 firm fixed price SBIR Phase II contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Heliowave Technologies LLC, a self-certified small disadvantaged business based in College Station, Texas. The contract supports the development of the HELIOSAFE-2 platform, a system for fast, label-free, automated evaluation of sterility, which aligns with DARPA's mission focus on chemical and biological defense capabilities. This award builds on a previous...
- This is a $225,000 Small Business Innovation Research (SBIR) Phase I contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Heliowave Technologies LLC, a small disadvantaged business located in College Station, Texas. The contract is for the development of the HELIOSAFE platform, a system for the fast, label-free, and automated evaluation of sterility, which is directly relevant to DARPA's mission focus on chemical and biological defense capabilities. The contract was...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Celartia, Inc., a small disadvantaged business, for the development of a fully automated system for cell therapy processing. The contract has a period of performance from September 13, 2021 to June 12, 2022 and a ceiling value of $393,312. The contract was awarded under a total small business set-aside. The original...
- The National Institutes of Health awarded Tessera Therapeutics, Inc., a federal contract worth $41.3 million to develop Gene Writer genome engineering technology for in vivo CAR-T cell therapy applications. The contract, structured as an Other Transaction Agreement and awarded on September 23, 2025, represents the NIH's investment in advancing cell and gene therapy approaches, which are among the agency's priority research areas. The work will be performed at Tessera's facility in Somerville,...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute, a civilian agency, to Nanohmics Inc., a small for-profit technology company based in Austin, Texas. The contract, valued at $299,999.00, is for the development of a compact cell-free DNA detection array under SBIR Topic 353. As a total small business set-aside contract, this award supports Nanohmics' capabilities in advanced electronics, optics, sensors, and imaging systems,...
- The National Institutes of Health has awarded Global Life Sciences Solutions USA LLC, a subsidiary of Danaher Corporation based in Marlborough, Massachusetts, an Other Transaction Agreement valued at $40.1M for CRISPR delivery and manufacturing innovation focused on minimal-cost-of-goods cancer and HIV therapies via in vivo immune engineering. The contract, awarded on September 25, 2025, extends through September 24, 2031, and does not utilize a small business set-aside designation. Global...
- This $1,999,646 firm fixed price definitive contract was awarded by the National Cancer Institute to Indee Inc., a biotechnology startup that develops a non-viral delivery platform called Hydropore for engineered cell therapies. The contract, which was set aside for total small businesses, is for research and development services focused on a microfluidic vortex shedding method to enable efficient genetic modification of cells for use in cell-based immunotherapies. This contract builds upon...
- The Department of Health and Human Services' National Institutes of Health (NIH) awarded a $46,411.00 firm fixed price purchase order to 10X Genomics, Inc., a small business that specializes in life sciences technology, to provide reagent kits. The award has a completion date of August 21, 2020. 10X Genomics previously held an indefinite delivery contract valued up to $750,000 with the NIH's National Institute of Neurological Disorders and Stroke to supply optimization slides, reagent kits,...